Display Settings:

Format

Send to:

Choose Destination

    J Neurosci. 2009 Jan 21;29(3):630-7.

    Axonal protective effects of the myelin-associated glycoprotein.

    Nguyen T, Mehta NR, Conant K, Kim KJ, Jones M, Calabresi PA, Melli G, Hoke A, Schnaar RL, Ming GL, Song H, Keswani SC, Griffin JW.

    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. tnguyena@jhmi.edu

    Progressive axonal degeneration follows demyelination in many neurological diseases, including multiple sclerosis and inherited demyelinating neuropathies, such as Charcot-Marie-Tooth disease. One glial molecule, the myelin-associated glycoprotein (MAG), located in the adaxonal plasmalemma of myelin-producing cells, is known to signal to the axon and to modulate axonal caliber through phosphorylation of axonal neurofilament proteins. This report establishes for the first time that MAG also promotes resistance to axonal injury and prevents axonal degeneration both in cell culture and in vivo. This effect on axonal stability depends on the RGD domain around arginine 118 in the extracellular portion of MAG, but it is independent of Nogo signaling in the axon. Exploiting this pathway may lead to therapeutic strategies for neurological diseases characterized by axonal loss.

    PMID: 19158290 [PubMed - indexed for MEDLINE]

    PMCID: 2774126

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Vincristine (Oncovin®, Vincasar®)

      Your doctor has ordered the drug vincristine to help treat your illness. The drug is given by injection into a vein.